ArticleBMC cardiovascular disorders2026
Fulminant cholesterol crystal embolism syndrome triggered by Vein of Marshall ethanol infusion: a case report.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCholesterol crystal embolism syndrome (CCES) represents a catastrophic complication of endovascular procedures. While mechanical trauma during left atrial catheter ablation acts as a known trigger, the specific embolic risks associated with Vein of Marshall ethanol infusion (VOM-EI) remain unexplored. CASE PRESENTATION: A 66-year-old male with severe atherosclerosis and chronic kidney disease underwent persistent atrial fibrillation ablation involving VOM-EI (8 mL of ≥ 99.7% dehydrated ethanol). Six hours post-procedure, he developed extensive, non-pruritic livedo reticularis. He remained hemodynamically stable (lowest blood pressure 111/78 mmHg) but rapidly progressed to anuric acute kidney injury (creatinine peaking at 542 µmol/L) and severe systemic inflammation. Diagnostic evaluation effectively ruled out contrast-induced nephropathy, hypotensive acute tubular necrosis, and autoimmune vasculitis. Given the rapid deterioration, specific eosinophiluria testing and renal biopsy were deferred; however, sterile pyuria, classic skin lesions, and recent vascular intervention established a highly probable clinical diagnosis of CCES. Treatment with intermittent hemodialysis and high-dose intravenous methylprednisolone (40 mg/day) rapidly suppressed the inflammatory storm and facilitated substantial renal recovery.
conclusionsIn patients with severe aortic plaque burden, VOM-EI, alongside established factors like transseptal catheter manipulation and systemic anticoagulation, may act as a potential trigger for CCES. Although a definitive diagnosis via biopsy was not feasible, we believe that early recognition and prompt corticosteroid therapy contributed substantially to the patient's clinical recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.